Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease

Science Translational Medicine

Volumn 8, Issue 368, 2016, Pages

  Ghosh, Anamitra ^a   Tyson, Trevor ^a   George, Sonia ^a   Hildebrandt, Erin N ^a   Steiner, Jennifer A ^a   Madaj, Zachary ^a   Schulz, Emily ^a   MacHiela, Emily ^a   McDonald, William G ^b   Galvis, Martha L Escobar ^a   Kordower, Jeffrey H ^a,c   Van Raamsdonk, Jeremy M ^a   Colca, Jerry R ^b   Brundin, Patrik ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Metabolic Solutions Development Company   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ANTIINFLAMMATORY AGENT; DOPAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL PYRUVATE CARRIER; MSDC 0160; NEUROPROTECTIVE AGENT; PYRUVIC ACID; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; MSDC-0160; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPHAGY; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; ENZYME REGULATION; GLIA CELL; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MALE; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; CHEMISTRY; DEGENERATIVE DISEASE; DISEASE MODEL; HETEROZYGOTE; IMMUNOLOGY; INFLAMMATION; METABOLISM; MITOCHONDRION; NERVE CELL; OXYGEN CONSUMPTION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; BEHAVIOR, ANIMAL; BRAIN; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HETEROZYGOTE; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PYRIDINES; PYRUVIC ACID; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; THIAZOLIDINEDIONES;

EID: 85003601650     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag2210     Document Type: Article

References (98)

1. R. B. Postuma, D. Berg, M. Stern, W. Poewe, C. W. Olanow, W. Oertel, J. Obeso, K. Marek, I. Litvan, A. E. Lang, G. Halliday, C. G. Goetz, T. Gasser, B. Dubois, P. Chan, B. R. Bloem, C. H. Adler, G. Deuschl, MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30, 1591-1601 (2015).
2. D. Berg, R. B. Postuma, B. Bloem, P. Chan, B. Dubois, T. Gasser, C. G. Goetz, G. M. Halliday, J. Hardy, A. E. Lang, I. Litvan, K. Marek, J. Obeso, W. Oertel, C. W. Olanow, W. Poewe, M. Stern, G. Deuschl, Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29, 454-462 (2014).
3. B. J. Ryan, S. Hoek, E. A. Fon, R. Wade-Martins, Mitochondrial dysfunction and mitophagy in Parkinson's: From familial to sporadic disease. Trends Biochem. Sci. 40, 200-210 (2015).
4. I. Ahmed, Y. Liang, S. Schools, V. L. Dawson, T. M. Dawson, J. M. Savitt, Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J. Neurosci. 32, 16503-16509 (2012).
5. C. Cebrián, J. D. Loike, D. Sulzer, Neuroinflammation in Parkinson's disease animal models: A cell stress response or a step in neurodegeneration?. Curr. Top. Behav. Neurosci. 22, 237-270 (2015).
6. L. V. Kalia, S. K. Kalia, A. E. Lang, Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30, 1442-1450 (2015).
7. D. Athauda, T. Foltynie, The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat. Rev. Neurol. 11, 25-40 (2015).
8. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind randomised trial. Lancet Neurol. 14, 795-803 (2015).
9. Parkinson Study Group QE3 Investigators, M. F. Beal, D. Oakes, I. Shoulson, C. Henchcliffe, W. R. Galpern, R. Haas, J. L. Juncos, J. G. Nutt, T. S. Voss, B. Ravina, C. M. Shults, K. Helles, V. Snively, M. F. Lew, B. Griebner, A. Watts, S. Gao, E. Pourcher, L. Bond, K. Kompoliti, P. Agarwal, C. Sia, M. Jog, L. Cole, M. Sultana, R. Kurlan, I. Richard, C. Deeley, C. H. Waters, A. Figueroa, A. Arkun, M. Brodsky, W. G. Ondo, C. B. Hunter, J. Jimenez-Shahed, A. Palao, J. M. Miyasaki, J. So, J. Tetrud, L. Reys, K. Smith, C. Singer, A. Blenke, D. S. Russell, C. Cotto, J. H. Friedman, M. Lannon, L. Zhang, E. Drasby, R. Kumar, T. Subramanian, D. S. Ford, D. A. Grimes, D. Cote, J. Conway, A. D. Siderowf, M. L. Evatt, B. Sommerfeld, A. N. Lieberman, M. S. Okun, R. L. Rodriguez, S. Merritt, C. L. Swartz, W. R. W. Martin, P. King, N. Stover, S. Guthrie, R. L. Watts, A. Ahmed, H. H. Fernandez, A. Winters, Z. Mari, T. M. Dawson, B. Dunlop, A. S. Feigin, B. Shannon, M. J. Nirenberg, M. Ogg, S. A. Ellias, C.-A. Thomas, K. Frei, I. Bodis-Wollner, S. Glazman, T. Mayer, R. A. Hauser, R. Pahwa, A. Langhammer, R. Ranawaya, L. Derwent, K. D. Sethi, B. Farrow, R. Prakash, I. Litvan, A. Robinson, A. Sahay, M. Gartner, V. K. Hinson, S. Markind, M. Pelikan, J. S. Perlmutter, J. Hartlein, E. Molho, S. Evans, C. H. Adler, A. Duffy, M. Lind, L. Elmer, K. Davis, J. Spears, S. Wilson, M. A. Leehey, N. Hermanowicz, S. Niswonger, H. A. Shill, S. Obradov, A. Rajput, M. Cowper, S. Lessig, D. Song, D. Fontaine, C. Zadikoff, K. Williams, K. A. Blindauer, J. Bergholte, C. S. Propsom, M. A. Stacy, J. Field, D. Mihaila, M. Chilton, E. Y. Uc, J. Sieren, D. K. Simon, L. Kraics, A. Silver, J. T. Boyd, R. W. Hamill, C. Ingvoldstad, J. Young, K. Thomas, S. K. Kostyk, J. Wojcieszek, R. F. Pfeiffer, M. Panisset, M. Beland, S. G. Reich, M. Cines, N. Zappala, J. Rivest, R. Zweig, L. P. Lumina, C. L. Hilliard, S. Grill, M. Kellermann, P. Tuite, S. Rolandelli, U. J. Kang, J. Young, J. Rao, M. M. Cook, L. Severt, K. Boyar, A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit. JAMA Neurol. 71, 543-552 (2014).
10. B. J. Snow, F. L. Rolfe, M. M. Lockhart, C. M. Frampton, J. D. O'Sullivan, V. Fung, R. A. J. Smith, M. P. Murphy, K. M. Taylor; Protect Study Group, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670-1674 (2010).
11. C. W. Olanow, O. Rascol, R. Hauser, P. D. Feigin, J. Jankovic, A. Lang, W. Langston, E. Melamed, W. Poewe, F. Stocchi, E. Tolosa; ADAGIO Study Investigators, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278 (2009).
12. Parkinson Study Group PRECEPT Investigators, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69, 1480-1490 (2007).
13. C. W. Olanow, A. H. V. Schapira, P. A. LeWitt, K. Kieburtz, D. Sauer, G. Olivieri, H. Pohlmann, J. Hubble, TCH346 as a neuroprotective drug in Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol. 5, 1013-1020 (2006).
14. NINDS NET-PD Investigators, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664-671 (2006).
15. L. R. Gray, S. C. Tompkins, E. B. Taylor, Regulation of pyruvate metabolism and human disease. Cell. Mol. Life Sci. 71, 2577-2604 (2014).
16. A. P. Halestrap, The mitochondrial pyruvate carrier: Has it been unearthed at last? Cell Metab. 16, 141-143 (2012).
17. D. K. Bricker, E. B. Taylor, J. C. Schell, T. Orsak, A. Boutron, Y.-C. Chen, J. E. Cox, C. M. Cardon, J. G. Van Vranken, N. Dephoure, C. Redin, S. Boudina, S. P. Gygi, M. Brivet, C. S. Thummel, J. Rutter, A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337, 96-100 (2012).
18. S. Herzig, E. Raemy, S. Montessuit, J.-L. Veuthey, N. Zamboni, B. Westermann, E. R. S. Kunji, J.-C. Martinou, Identification and functional expression of the mitochondrial pyruvate carrier. Science 337, 93-96 (2012).
19. P. A. Vigueira, K. S. McCommis, G. G. Schweitzer, M. S. Remedi, K. T. Chambers, X. Fu, W. G. McDonald, S. L. Cole, J. R. Colca, R. F. Kletzien, S. C. Burgess, B. N. Finck, Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep. 7, 2042-2053 (2014).
20. L. R. Gray, M. R. Sultana, A. J. Rauckhorst, L Oonthonpan, S. C. Tompkins, A. Sharma, X. Fu, R. Miao, A. D. Pewa, K. S. Brown, E. E. Lane, A. Dohlman, D. Zepeda-Orozco, J. Xie, J. Rutter, A. W. Norris, J. E. Cox, S. C. Burgess, M. J. Potthoff, E. B. Taylor, Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 22, 669-681 (2015).
21. K. S. McCommis, Z. Chen, X. Fu, W. G. McDonald, J. R. Colca, R. F. Kletzien, S. C. Burgess, B. N. Finck, Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 22, 682-694 (2015).
22. J. R. Colca, W. G. McDonald, G. S. Cavey, S. L. Cole, D. D. Holewa, A. S. Brightwell-Conrad, C. L. Wolfe, J. S. Wheeler, K. R. Coulter, P. M. Kilkuskie, E. Gracheva, Y. Korshunova, M. Trusgnich, R. Karr, S. E. Wiley, A. S. Divakaruni, A. N. Murphy, P. A. Vigueira, B. N. Finck, R. F. Kletzien, Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-Relationship to newly identified mitochondrial pyruvate carrier proteins. PLOS ONE 8, e61551 (2013).
23. J. R. Colca, W. G. McDonald, R. F. Kletzien, Mitochondrial target of thiazolidinediones. Diabetes Obes. Metab. 16, 1048-1054 (2014).
24. A. S. Divakaruni, S. E. Wiley, G. W. Rogers, A. Y. Andreyev, S. Petrosyan, M. Loviscach, E. A. Wall, N. Yadava, A. P. Heuck, D. A. Ferrick, R. R. Henry, W. G. McDonald, J. R. Colca, M. I. Simon, T. P. Ciaraldi, A. N. Murphy, Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. U.S.A. 110, 5422-5427 (2013).
25. C. A. Hofmann, J. R. Colca, New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15, 1075-1078 (1992).
26. N. M. Vacanti, A. S. Divakaruni, C. R. Green, S. J. Parker, R. R. Henry, T. P. Ciaraldi, A. N. Murphy, C. M. Metallo, Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol. Cell 56, 425-435 (2014).
27. C. Yang, B. Ko, C. T. Hensley, L. Jiang, A. T. Wasti, J. Kim, J. Sudderth, M. A. Calvaruso, L. Lumata, M. Mitsche, J. Rutter, M. E. Merritt, R. J. DeBerardinis, Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 56, 414-424 (2014).
28. R. Scatena, G. E. Martorana, P. Bottoni, B. Giardina, Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life 56, 477-482 (2004).
29. J. R. Colca, The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin. Drug Discov. 10, 1259-1270 (2015).
30. D. Levin, S. Bell, R. Sund, S. A. Hartikainen, J. Tuomilehto, E. Pukkala, I. Keskimäki, E. Badrick, A. G. Renehan, I. E. Buchan, S. L. Bowker, J. K. Minhas-Sandhu, Z. Zafari, C. Marra, J. A. Johnson, B. H. Stricker, A. G. Uitterlinden, A. Hofman, R. Ruiter, C. E. de Keyser, T. M. MacDonald, S. H. Wild, P. M. McKeigue, H. M. Colhoun; Scottish Diabetes Research Network Epidemiology Group, Diabetes and Cancer Research Consortium, Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493-504 (2015).
31. J. D. Lewis, L. A. Habel, C. P. Quesenberry, B. L. Strom, T. Peng, M. M. Hedderson, S. F. Ehrlich, R. Mamtani, W. Bilker, D. J. Vaughn, L. Nessel, S. K. Van Den Eeden, A. Ferrara, Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314, 265-277 (2015).
32. R. Brauer, K. Bhaskaran, N. Chaturvedi, D. T. Dexter, L. Smeeth, I. Douglas, Glitazone treatment and incidence of Parkinson's disease among people with diabetes: A retrospective cohort study. PLOS Med. 12, e1001854 (2015).
33. R. Kapadia, J.-H. Yi, R. Vemuganti, Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci. 13, 1813-1826 (2008).
34. A. R. Carta, PPAR-g: Therapeutic prospects in Parkinson's disease. Curr. Drug Targets 14, 743-751 (2013).
35. J. A. Santiago, J. A. Potashkin, Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLOS ONE 8, e83940 (2013).
36. I. Aviles-Olmos, P. Limousin, A. Lees, T. Foltynie, Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136, 374-384 (2013).
37. J. A. Santiago, J. A. Potashkin, System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol. Dis. 72, 84-91 (2014).
38. C. A. Downs, M. S. Faulkner, Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J. Diabetes 6, 554-565 (2015).
39. C. W. Bolten, P. M. Blanner, W. G. McDonald, N. R. Staten, R. A. Mazzarella, G. B. Arhancet, M. F. Meier, D. J. Weiss, P. M. Sullivan, A. E. Hromockyj, R. F. Kletzien, J. R. Colca, Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. Gene Regul. Syst. Bio. 1, 73-82 (2007).
40. J. R. Colca, S. P. Tanis, W. G. McDonald, R. F. Kletzien, Insulin sensitizers in 2013: New insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin. Investig. Drugs 23, 1-7 (2014).
41. J. R. Colca, J. T. VanderLugt, W. J. Adams, A. Shashlo, W. G. McDonald, J. Liang, R. Zhou, D. G. Orloff, Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin. Pharmacol. Ther. 93, 352-359 (2013).
42. R. C. Shah, D. C. Matthews, R. D. Andrews, A. W. Capuano, D. A. Fleischman, J. T. VanderLugt, J. R. Colca, An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr. Alzheimer Res. 11, 564-573 (2014).
43. J. Lotharius, S. Barg, P. Wiekop, C. Lundberg, H. K. Raymon, P. Brundin, Effect of mutant a-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 38884-38894 (2002).
44. A. Ghosh, H. Saminathan, A. Kanthasamy, V. Anantharam, H. Jin, G. Sondarva, D. S. Harischandra, Z. Qian, A. Rana, A. G. Kanthasamy, The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: Relevance to the pathogenesis of Parkinson disease. J. Biol. Chem. 288, 21955-21971 (2013).
45. S. Cao, C. C. Gelwix, K. A. Caldwell, G. A. Caldwell, Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 25, 3801-3812 (2005).
46. L. A. Berkowitz, S. Hamamichi, A. L. Knight, A. J. Harrington, G. A. Caldwell, K. A. Caldwell, Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. J. Vis. Exp. 2008, 835 (2008).
47. S. Przedborski, V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, S. Vukosavic, G. Almer, The parkinsonian toxin MPTP: Action and mechanism. Restor. Neurol. Neurosci. 16, 135-142 (2000).
48. A. Ghosh, A. Kanthasamy, J. Joseph, V. Anantharam, P. Srivastava, B. P. Dranka, B. Kalyanaraman, A. G. Kanthasamy, Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J. Neuroinflammation 9, 241 (2012).
49. V. Jackson-Lewis, S. Przedborski, Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2, 141-151 (2007).
50. J. A. L. Hutter-Saunders, H. E. Gendelman, R. L. Mosley, Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. J. Neuroimmune Pharmacol. 7, 279-288 (2012).
51. A. Ghosh, K. Chandran, S. V. Kalivendi, J. Joseph, W. E. Antholine, C. J. Hillard, A. Kanthasamy, A. Kanthasamy, B. Kalyanaraman, Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic. Biol. Med. 49, 1674-1684 (2010).
52. L. Sonnier, G. Le Pen, A. Hartmann, J.-C. Bizot, F. Trovero, M.-O. Krebs, A. Prochiantz, Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1. J. Neurosci. 27, 1063-1071 (2007).
53. U. Nordström, G. Beauvais, A. Ghosh, B. C. Pulikkaparambil Sasidharan, M. Lundblad, J. Fuchs, R. L. Joshi, J. W. Lipton, A. Roholt, S. Medicetty, T. N. Feinstein, J. A. Steiner, M. L. Escobar Galvis, A. Prochiantz, P. Brundin, Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol. Dis. 73, 70-82 (2015).
54. J. Q. Trojanowski, V. M.-Y. Lee, Aggregation of neurofilament and a-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55, 151-152 (1998).
55. W. Xu, L. Tan, J.-T. Yu, The link between the SNCA gene and parkinsonism. Neurobiol. Aging 36, 1505-1518 (2015).
56. J. Zhao, B. Zhai, S. P. Gygi, A. L. Goldberg, mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc. Natl. Acad. Sci. U.S.A. 112, 15790-15797 (2015).
57. Y. Zhang, J. Nicholatos, J. R. Dreier, S. J. H. Ricoult, S. B. Widenmaier, G. S. Hotamisligil, D. J. Kwiatkowski, B. D. Manning, Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 513, 440-443 (2014).
58. J. L. Jewell, K.-L. Guan, Nutrient signaling to mTOR and cell growth. Trends Biochem. Sci. 38, 233-242 (2013).
59. S. G. Kim, G. R. Buel, J. Blenis, Nutrient regulation of the mTOR complex 1 signaling pathway. Mol. Cells 35, 463-473 (2013).
60. P. L. McGeer, E. G. McGeer, Glial reactions in Parkinson's disease. Mov. Disord. 23, 474-483 (2008).
61. E. Blasi, R. Barluzzi, V. Bocchini, R. Mazzolla, F. Bistoni, Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J. Neuroimmunol. 27, 229-237 (1990).
62. A. S. Harms, M. G. Tansey, Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. Methods Mol. Biol. 1041, 33-39 (2013).
63. A. Ghosh, A. Roy, X. Liu, J. H. Kordower, E. J. Mufson, D. M. Hartley, S. Ghosh, R. L. Mosley, H. E. Gendelman, K. Pahan, Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 104, 18754-18759 (2007).
64. J. A. Santiago, J. A. Potashkin, Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 112, 2257-2262 (2015).
65. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, T. Soderlund, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. Foltynie, Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736 (2013).
66. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P. Ell, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. Foltynie, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344 (2014).
67. C. Malagelada, Z. H. Jin, L. A. Greene, RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 28, 14363-14371 (2008).
68. C. Malagelada, E. J. Ryu, S. C. Biswas, V. Jackson-Lewis, L. A. Greene, RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 26, 9996-10005 (2006).
69. J. Deguil, F. Chavant, C. Lafay-Chebassier, M.-C. Pérault-Pochat, B. Fauconneau, S. Pain, Time course of MPTP toxicity on translational control protein expression in mice brain. Toxicol. Lett. 196, 51-55 (2010).
70. X.-Q. Bao, X.-C. Kong, C. Qian, D. Zhang, FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models. Neuroscience 202, 396-404 (2012).
71. M. Cao, X. Tan, W. Jin, H. Zheng, W. Xu, Y. Rui, L. Li, J. Cao, X. Wu, G. Cui, K. Ke, Y. Gao, Upregulation of Ras homolog enriched in the brain (Rheb) in lipopolysaccharide-induced neuroinflammation. Neurochem. Int. 62, 406-417 (2013).
72. C. Malagelada, Z. H. Jin, V. Jackson-Lewis, S. Przedborski, L. A. Greene, Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 30, 1166-1175 (2010).
73. D. C. Fingar, J. Blenis, Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171 (2004).
74. H. W. Yung, D. S. Charnock-Jones, G. J. Burton, Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLOS ONE 6, e17894 (2011).
75. D. J. Klionsky, S. D. Emr, Autophagy as a regulated pathway of cellular degradation. Science 290, 1717-1721 (2000).
76. P. Anglade, S. Vyas, E. C. Hirsch, Y. Agid, Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 12, 603-610 (1997).
77. A. R. Winslow, C.-W. Chen, S. Corrochano, A. Acevedo-Arozena, D. E. Gordon, A. A. Peden, M. Lichtenberg, F. M. Menzies, B. Ravikumar, S. Imarisio, S. Brown, C. J. O'Kane D. C. Rubinsztein, α-Synuclein impairs macroautophagy: Implications for Parkinson's disease. J. Cell Biol. 190, 1023-1037 (2010).
78. B. Dehay, J. Bové, N. Rodríguez-Muela, C. Perier, A. Recasens, P. Boya, M. Vila, Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535-12544 (2010).
79. H.-F. Zheng, Y.-P. Yang, L.-F. Hu, M.-X. Wang, F. Wang, L.-D. Cao, D. Li, C.-J. Mao, K.-P. Xiong, J.-D. Wang, C.-F. Liu, Autophagic impairment contributes to systemic inflammation-induced dopaminergic neuron loss in the midbrain. PLOS ONE 8, e70472 (2013).
80. E. Aflaki, N. Moaven, D. K. Borger, G. Lopez, W. Westbroek, J. J. Chae, J. Marugan, S. Patnaik, E. Maniwang, A. N. Gonzalez, E. Sidransky, Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 15, 77-88 (2016).
81. P. Prajapati, L. Sripada, K. Singh, K. Bhatelia, R. Singh, R. Singh, TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. Biochim. Biophys. Acta 1852, 451-461 (2015).
82. P. L. McGeer, S. Itagaki, B. E. Boyes, E. G. McGeer, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291 (1988).
83. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, T. Nagatsu, Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208-210 (1994).
84. R. J. Dobbs, A. Charlett, A. G. Purkiss, S. M. Dobbs, C. Weller, D. W. Peterson, Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34-41 (1999).
85. T. Weichhart, M. D. Säemann, The multiple facets of mTOR in immunity. Trends Immunol. 30, 218-226 (2009).
86. F. Schmitz, A. Heit, S. Dreher, K. Eisenächer, J. Mages, T. Haas, A. Krug, K.-P. Janssen, C. J. Kirschning, H. Wagner, Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur. J. Immunol. 38, 2981-2992 (2008).
87. C. F. Phelix, G. Perry, S. F. McHardy, Molecular docking analysis of mitochondrial pyruvate carrier (MPC) 1 and 2 with pyruvate and inhibitors: Thiazolidinediones currently in clinical trials to delay mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 11, P760-P761 (2015).
88. M. P. Mattson, Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy. J. Parkinsons Dis. 4, 1-13 (2014).
89. P. Brundin, R. Wyse, Parkinson disease: Laying the foundations for disease-modifying therapies in PD. Nat. Rev. Neurol. 11, 553-555 (2015).
90. J. A. Santiago, J. A. Potashkin, Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176-186 (2013).
91. M. Stumvoll, H.-U. Häring, Glitazones: Clinical effects and molecular mechanisms. Ann. Med. 34, 217-224 (2002).
92. D. C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.-K. Choi, H. Ischiropoulos, S. Przedborski, Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771 (2002).
93. S. Brenner, The genetics of Caenorhabditis elegans. Genetics 77, 71-94 (1974).
94. D. Bates, M. Mächler, B. M. Bolker, S. C. Walker, Fitting linear mixed-effects models using lme4. ArXiv: 1406.5823v1 (2014).
95. C. Krueger, L. Tian, A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. Biol. Res. Nurs. 6, 151-157 (2004).
96. Y. Benjamini, D. Yekutieli, The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 29, 1165-1188 (2001).
97. R Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2013).
98. D. Scholz, D. Pöltl, A. Genewsky, M. Weng, T. Waldmann, S. Schildknecht, M. Leist, Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J. Neurochem. 119, 957-971 (2011).